Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,402
Employees1,402
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,402
Employees1,402

IONS Key Statistics

Market cap
9.62B
Market cap9.62B
Price-Earnings ratio
-27.71
Price-Earnings ratio-27.71
Dividend yield
Dividend yield
Average volume
5.14M
Average volume5.14M
High today
$65.32
High today$65.32
Low today
$58.18
Low today$58.18
Open price
$64.27
Open price$64.27
Volume
11.44M
Volume11.44M
52 Week high
$86.74
52 Week high$86.74
52 Week low
$40.03
52 Week low$40.03

Stock Snapshot

With a market cap of 9.62B, Ionis Pharmaceuticals(IONS) trades at $58.20. The stock has a price-to-earnings ratio of -27.71.

On 2026-07-12, Ionis Pharmaceuticals(IONS) stock moved within a range of $58.18 to $65.32. With shares now at $58.20, the stock is trading +0.0% above its intraday low and -10.9% below the session's peak.

Trading volume for Ionis Pharmaceuticals(IONS) stock has reached 11.44M, versus its average volume of 5.14M.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

Over the past 52 weeks, Ionis Pharmaceuticals(IONS) stock has traded between a high of $86.74 and a low of $40.03.

IONS News

Simply Wall St 16h
Ionis Pharmaceuticals Faces A Key Setback As Eplontersen Misses In Phase 3

Ionis Pharmaceuticals (NasdaqGS:IONS) and AstraZeneca reported that their Phase 3 trial of eplontersen in transthyretin mediated amyloid cardiomyopathy did not...

Ionis Pharmaceuticals Faces A Key Setback As Eplontersen Misses In Phase 3
24/7 Wall St. 2d
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up

The Motley Fool told its subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005. Stock Advisor still publishes two new stock picks every month —...

Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
Benzinga 2d
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

• Ionis Pharmaceuticals stock is taking a hit today. What’s pressuring IONS stock? In patients receiving contemporary standard of care, including a majority tr...

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Analyst ratings

88%

of 26 ratings
Buy
88.5%
Hold
11.5%
Sell
0%

More IONS News

TipRanks 2d
H.C. Wainwright trims Ionis price target, says trial failure reaction ‘overdone’

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $125 from $130 and keeps a Buy rating on the shares....

TipRanks 2d
Intellia Therapeutics price target raised to $17 from $12 at Wedbush

Wedbush raised the firm’s price target on Intellia Therapeutics to $17 from $12 and keeps a Neutral rating on the shares. Relevant to Intellia Therapeutics (NTL...

TipRanks 2d
Ionis Pharmaceuticals Reaffirms 2026 Financial Guidance Outlook

The latest update is out from Ionis Pharmaceuticals ( (IONS) ). Ionis Pharmaceuticals reaffirmed its previously announced financial guidance for the fiscal yea...

TipRanks 2d
Eric Joseph Lifts Ionis Price Target to $100, Reaffirming Buy Amid Adjusted Pipeline and Royalty Assumptions

Analyst Eric Joseph of Citi maintained a Buy rating on Ionis Pharmaceuticals, boosting the price target to $100.00. Unlock powerful investing tools and data-dr...

TipRanks 3d
Ionis, AstraZeneca report Phase 3 eplontersen setback

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 3d
Ionis Pharmaceuticals Stock Slammed by Phase 3 Trial Results

Ionis Pharmaceuticals (IONS) stock was hit hard on Thursday after the biopharmaceutical company provided a clinical trial update. The company and partner AstraZ...

TipRanks 3d
Morning Movers: Ionis and AstraZeneca sink after trial misses endpoint

Markets are attempting to recover this morning after Wednesday’s geopolitical-driven selloff, with U.S. stock futures moving modestly higher as oil prices retre...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.